ONL Therapeutics to Present at the XXVth Biennial Meeting
Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-13, 19:03
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-02, 19:05
ONL Therapeutics to Present at 2023 BIO CEO & Investor
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for...
